Neurodegenerative R&D's Harsh Reality: Alector's Collapse vs. Ionis's Resilience Amid Partner Exits

Related Articles

Rackspace's AI Ambition Collides with a Harsh Financial Reality

3 months ago

What Triggered GRAIL's Recent Stock Collapse

4 months ago

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

7 months ago

Consumer Resilience vs. Retail Headwinds: Navigating Discretionary and Essential Goods Stocks

8 months ago

Category

You may also like

Stock News•1 months ago

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Biohaven's BHV-7000 epilepsy program received a partial clinical hold from the FDA, pausing new patient enrollment while the lead pivotal study's timeline remains unchanged.

BHVN

Share

Stock News•3 months ago

Ionis Pharmaceuticals: The Heartbreak Is Priced In

Ionis Pharmaceuticals fell sharply after ATTR-CM and tominersen setbacks, but core assets remain intact. Tryngolza leads value with strong sHTG data; $1.9B liquidity supports a path to 2028 breakeven.

IONS

Share

Stock News•3 months ago

Alector and GSK partnership to end after dementia, Alzheimer's drug failures

Alector's neuroscience collaboration with GSK ended after two experimental antibody drugs failed in clinical trials. The termination removes a key partnership and potential milestone revenue for Alect...

ALEC

Share